Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-343P is a processed pseudogene derived from the U6 small nuclear RNA gene family. U6 snRNA plays an essential role in the spliceosome assembly and intron excision from pre-mRNA in eukaryotic cells[1][3]. However, RNU6-343P itself does not encode a functional RNA and is not transcribed into a protein; it is a relic of retrotransposition events in the genome[4][5]. Processed pseudogenes such as RNU6-343P typically result from reverse transcription of RNA and genomic integration, often facilitated by LINE-1 elements. The presence of many U6 pseudogenes in the genome reflects the evolutionary importance of U6 snRNA but does not confer direct biological or pathological activity to the pseudogenes themselves[3][5]. Key distinctions: - Functional U6 snRNA: Involved in pre-mRNA splicing, essential for eukaryotic gene expression[1][3]. - RNU6-343P pseudogene: Genomic inactive copy, no known function, not a therapeutic or drug target[4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 343, pseudogene (RNU6-343P).